{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:32:33Z","timestamp":1778056353741,"version":"3.51.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1097\/md.0000000000007988","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T23:03:49Z","timestamp":1504047829000},"page":"e7988","source":"Crossref","is-referenced-by-count":5,"title":["Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients"],"prefix":"10.1097","volume":"96","author":[{"given":"Mengyao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimita","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Freise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-62-20210226","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","article-title":"Non-Hodgkin lymphoma","volume":"380","author":"Shankland","year":"2012","journal-title":"Lancet"},{"key":"R2-62-20210226","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.mayocp.2015.04.025","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"R3-62-20210226","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: bridging the divide","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"R4-62-20210226","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-13-0316","article-title":"Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals","volume":"19","author":"Shea","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R6-62-20210226","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.7150\/jca.18686","article-title":"Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials","volume":"8","author":"Agarwal","year":"2017","journal-title":"J Cancer"},{"key":"R7-62-20210226","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"R9-62-20210226","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R10-62-20210226","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/annonc\/mds289","article-title":"Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer","volume":"24","author":"Petrelli","year":"2013","journal-title":"Ann Oncol"},{"key":"R11-62-20210226","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/1078-0432.CCR-12-2502","article-title":"Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials","volume":"19","author":"Sidhu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R12-62-20210226","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1078-0432.CCR-14-1779","article-title":"Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor","volume":"21","author":"Ozer-Stillman","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R13-62-20210226","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/OTT.S36683","article-title":"Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology","volume":"5","author":"Sherrill","year":"2012","journal-title":"Onco Targets Ther"},{"key":"R14-62-20210226","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3747\/co.22.2119","article-title":"Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis","volume":"22","author":"Beauchemin","year":"2015","journal-title":"Curr Oncol"},{"key":"R15-62-20210226","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000375392","article-title":"Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data","volume":"38","author":"Cartier","year":"2015","journal-title":"Oncol Res Treat"},{"key":"R16-62-20210226","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","article-title":"Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points","volume":"22","author":"Lee","year":"2011","journal-title":"Ann Oncol"},{"key":"R17-62-20210226","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/blood.V108.11.4720.4720","article-title":"Repsonse to re-treatment with rituximab plus salvage-chemotherapy in refractory or relapsed aggressive non-Hodgkin's lymphoma","volume":"108","author":"Borgerding","year":"2006","journal-title":"Blood"},{"key":"R18-62-20210226","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1182\/blood.V108.11.4707.4707","article-title":"Re-treatment with rituximab plus chemotherapy in patients with aggressive lymphoma treated previously with CHOP or CHOP-like combinations plus rituximab","volume":"108","author":"Palacios","year":"2006","journal-title":"Blood"},{"key":"R19-62-20210226","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.2008.07383.x","article-title":"Use of rituximab in diffuse large B-cell lymphoma in the salvage setting","volume":"143","author":"Gisselbrecht","year":"2008","journal-title":"Br J Haematol"},{"key":"R20-62-20210226","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00277-009-0820-9","article-title":"Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma","volume":"89","author":"Borgerding","year":"2010","journal-title":"Ann Hematol"},{"key":"R21-62-20210226","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10428190903503404","article-title":"Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphoma: a single institution case control study","volume":"51","author":"Johnston","year":"2010","journal-title":"Leuk Lymphoma"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:32:08Z","timestamp":1620959528000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201709010-00062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":19,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007988","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}